title: Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research.
abstract: The aim of this study is to review advances in basic and clinical allergic rhinitis (AR) research over the past decade that have been conducted using controlled allergen challenge facility (CACF) models of allergen challenge. Databases, including PubMed, Medline, and Web of Science were searched for articles employing an ambient pollen exposure in a controlled facility to study AR, published between 2004 and the present date, using the terms as follows: CACF, Environmental Exposure Unit (EEU), Vienna Challenge Chamber (VCC), Fraunhofer Institute Environmental Challenge Chamber, Atlanta Allergen Exposure Unit, Biogenics Research Chamber, Allergen BioCube, Chiba and Osaka Environmental Challenge Chamber, exposure unit, challenge chamber, or environmental exposure chamber. Articles were then selected for relevance to the goals of the present review, including important contributions toward clinical and/or basic science allergy research. CACFs offer sensitive, specific, and reproducible methodology for allergen challenge. They have been employed since the 1980s and offer distinct advantages over traditional in-season multicentre trials when evaluating new treatments for AR. They have provided clinically applicable efficacy and pharmacologic information about important allergy medications, including antihistamines, decongestants, antileukotrienes, immunotherapies, and nasal steroids. CACF models have also contributed to basic science and novel/experimental therapy research. To date, no direct studies have been conducted comparing outcomes from one CACF to another. Over the past decade, CACF models have played an essential role in investigating the pathophysiology of AR and evaluating new therapies. The future opportunities for this model continue to expand.
authors.affiliation: Division of Allergy & Immunology, Department of Medicine, Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON, Canada.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: North
authors.forename: Mena
authors.initials: M
authors.lastname: Soliman
authors.forename: Terry
authors.initials: T
authors.lastname: Walker
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Steacy
authors.forename: Anne K
authors.initials: AK
authors.lastname: Ellis
mesh_terms: D000485:Allergens / Q000276:immunology*; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D004781:Environmental Exposure; D006801:Humans; D007167:Immunotherapy; D011058:Pollen / Q000276:immunology; D065631:Rhinitis, Allergic / Q000276:immunology*
chemical_list: D000485:Allergens; D018926:Anti-Allergic Agents